首页> 外文期刊>International Journal of Molecular Sciences >S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer
【24h】

S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer

机译:S100A10和癌症标志:结构,功能及其在卵巢癌中的新兴作用。

获取原文
           

摘要

S100A10, which is also known as p11, is located in the plasma membrane and forms a heterotetramer with annexin A2. The heterotetramer, comprising of two subunits of annexin A2 and S100A10, activates the plasminogen activation pathway, which is involved in cellular repair of normal tissues. Increased expression of annexin A2 and S100A10 in cancer cells leads to increased levels of plasmin—which promotes the degradation of the extracellular matrix—increased angiogenesis, and the invasion of the surrounding organs. Although many studies have investigated the functional role of annexin A2 in cancer cells, including ovarian cancer, S100A10 has been less studied. We recently demonstrated that high stromal annexin A2 and high cytoplasmic S100A10 expression is associated with a 3.4-fold increased risk of progression and 7.9-fold risk of death in ovarian cancer patients. Other studies have linked S100A10 with multidrug resistance in ovarian cancer; however, no functional studies to date have been performed in ovarian cancer cells. This article reviews the current understanding of S100A10 function in cancer with a particular focus on ovarian cancer.
机译:S100A10,也称为p11,位于质膜中,与膜联蛋白A2形成异源四聚体。由膜联蛋白A2和S100A10的两个亚基组成的异四聚体激活纤溶酶原激活途径,该途径参与正常组织的细胞修复。癌细胞中膜联蛋白A2和S100A10的表达增加导致纤溶酶水平升高,从而促进了细胞外基质的降解,从而增加了血管生成和周围器官的侵袭。尽管许多研究已经研究了膜联蛋白A2在癌细胞(包括卵巢癌)中的功能,但对S100A10的研究较少。我们最近证明,在卵巢癌患者中,高间质膜联蛋白A2和高细胞质S100A10表达与进展风险增加3.4倍,死亡风险增加7.9倍有关。其他研究将S100A10与卵巢癌的多药耐药性联系起来。然而,迄今为止尚未在卵巢癌细胞中进行功能研究。本文回顾了目前对S100A10在癌症中的功能的了解,尤其是卵巢癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号